# Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

> **NCT05515315** · PHASE2 · RECRUITING · sponsor: **Fuzhou General Hospital** · enrollment: 93 (estimated)

## Conditions studied

- Immunotherapy Esophagus Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Albumin paclitaxel
- **DRUG:** Nedaplatin
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT05515315
- **Lead sponsor:** Fuzhou General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-31
- **Primary completion:** 2025-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05515315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05515315, "Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05515315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*